Business · 18/10/2024Updated: 10/17/2026 · 1 min read
FDA Clears TAVIST Tablet for Sale
Summary
The FDA has determined that TAVIST tablet, 2.68mg, was not withdrawn from sale due to safety or effectiveness concerns, allowing it to remain on the market and continue to be approved for use in ANDAs.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →